Survodutide reconstitution calculator
BI 456906 · glucagon/GLP-1 dual agonist
Survodutide is the other next-generation contender: a dual glucagon/GLP-1 agonist whose glucagon arm targets liver fat directly, making it the leading candidate in MASH (fatty liver disease) alongside its obesity program. It trails retatrutide in the weight-loss horse race but may win the liver indication.
Enter vial size, water volume, and the dose your provider gave you.
This tool converts the numbers you enter (dose ÷ concentration = volume). It never suggests a dose. The FDA has documented hospitalizations caused by mg / ml / unit conversion errors with vial-and-syringe products - if the readout surprises you, stop and verify with your prescriber or pharmacist.
Questions people actually search
What makes survodutide different from retatrutide?
Receptor count and emphasis: survodutide is a dual agonist (glucagon + GLP-1) with a strong liver signal - its Phase 2 MASH results showed biopsy improvements in a majority of treated patients. Retatrutide adds GIP as a third receptor and leads on pure weight-loss numbers.
When will survodutide be approved?
Phase 3 trials in obesity and MASH are ongoing as of August 2026; no submission has been announced. A realistic decision window is 2027-2028, trial results permitting - the same horizon as retatrutide.
Can you buy survodutide?
Not legitimately. It is an investigational drug available only in trials; the FDA's warnings about unapproved GLP-1 products sold online apply to it exactly as to retatrutide.